

Cantargia Receives Patent Approval in China

05 January 2018 | News

Cantargia is developing antibodies against IL1RAP for Solid Tumours



Cantargia is a biotech company that is developing antibody-based treatments for life-threatening diseases.

The company's main project, 'the immuno-oncology antibody CAN04' is undergoing a clinical phase I/IIa trial focusing on treatment of non-small cell lung cancer and pancreatic cancer.

The patent application which has now been approved in China refers to Cantargia's method of using IL1RAP as target molecule for treatment of several types of solid tumours, including breast cancer, colorectal cancer, lung cancer and malignant melanoma.

Cantargia already has the equivalent patent protection in other regions, including Europe, the United States and Japan.

The Chinese patent provides protection until 2032.